Improving glucose control in patients with diabetes following myocardial infarction: The role of a novel glycaemia monitoring strategy

niversity of Leeds0 个研究点目标入组 141 人开始时间: 2017年6月13日最近更新: 2023年7月25日

适应症

试验速览

2020 Protocol article in https://pubmed.ncbi.nlm.nih.gov/33081502/ protocol (added 23/10/2020) 2023 Results article in https://pubmed.ncbi.nlm.nih.gov/36516054/ (added 11/07/2023)

•1. Patients aged = 18 years
•2. Type 2 Diabetes Mellitus defined as a preadmission diagnosis
•3. Pre-admission treatment of hyperglycaemia with sulphonylurea and/or insulin, with or without additional hypoglycaemic agents
•4. MI defined as typical symptoms of cardiac ischaemia associated with a typical rise in troponin levels using the 99th percentile threshold cut-off as per the Third Universal Definition of MI. Patients with either ST-elevation MI (STEMI) or non-ST elevation MI (NSTEMI) are eligible to participate.
•5. Patient has provided written informed consent

•1. Solely diet-controlled T2DM preadmission
•2. Patient has active malignancy other than localised squamous cell or basal cell skin carcinoma.
•3. Patient who has a current pacemaker fitted, known to be pregnant or requiring dialysis.
•4. Patient is unable to follow study instructions or considered unsuitable for trial participation at the discretion of the treating clinician/nurse.
•5. Patient previously participated in the LIBERATES trial

发起方

niversity of Leeds